Market Research Logo

Conference Documentation: Superbugs & Superdrugs - Pushing financial incentives and collaborative incentives to accelerate clinical success

Conference Documentation: Superbugs & Superdrugs - Pushing financial incentives and collaborative incentives to accelerate clinical success

The threat of antibiotic- resistant microbes poses one of the biggest economic and health threats in our time, as microbes are becoming more resistant and fewer drugs are passing clinical trials successfully.

Moreover, the increase in global migration accelerates the spread as we have seen from Mers and Ebola viruses, as well as overconsumption and hospital acquired infections.

Thus, our 18th year in hosting Superbugs and Superdrugs continues to address the core challenges in the industry from: Investment, R&D to hospital hygiene, and consumer engagement and review current strategies.

We’re now seeing strong leaderships and collaborations to fund research and investment from the likes of: The Welcome Trust, IMI, and BARDA who are invited to share their funding strategies to strengthen the antiobiotics pipeline.


Day 1
8:30
Registration & Coffee
9:00
Chairman's Opening Remarks
Richard Bax, Senior Partner, TranScrip Partners
9:10
OPENING ADDRESS: Current status and future prospects
Richard Bax, Senior Partner, TranScrip Partners
9:50
Extending portfolio partnerships to strengthen the antibiotic pipeline
Christopher Houchens, Project Officer, BARDA
10:30
Morning Coffee
11:00
Making a material difference to healthcare
Andrew Cross, Director, ACT-Surfaces Ltd
11:40
Keynote Address: Fighting AMR and progressing public partnerships
Arjon Van Hengel, Scientific Officer, European Commission
12:20
Networking Lunch
13:20
A Global Health R&D Approach to Innovation, Conservation, and Access to New Antibiotic Treatments
Jean-Pierre Paccaud, Director of Business Development and Legal , Drugs for Neglected Diseases initiative (DNDi)
14:00
New insights of pathogen –host interactions and EU project - INFECT
Anna Norrby-Teglund, Professor, Head of Center for Infectious Medicine, Karolinska Institutet
14:40
Developing an antibiotic with potential for use in multiple therapeutic indications
Prabhavathi Fernandes, President and Chief Executive Officer, Cempra Pharmaceuticals
15:20
Afternoon Tea
15:50
Monoclonal antibody-based approaches to fight severe bacterial infections
Eszter Nagy, Co-founder, President and CSO, Arsanis Biosciences
16:30
New business models for antibiotics: where are we now?
Jorge Mestre-Ferrandiz, Director, Office of Health Economics (OHE)
17:10
Rapid diagnostic tools
Sam Whitehouse, Chief Operating Officer, QuantuMDX Group
17:50
Panel discussion: Tackling the major bottlenecks that hinder development of new antibacterial drugs
Richard Bax, Senior Partner, TranScrip Partners
17:50
Panel discussion: Tackling the major bottlenecks that hinder development of new antibacterial drugs
Prabhavathi Fernandes, President and Chief Executive Officer, Cempra Pharmaceuticals
17:50
Panel discussion: Tackling the major bottlenecks that hinder development of new antibacterial drugs
Andrew Cross, Director, ACT-Surfaces Ltd
17:50
Panel discussion: Tackling the major bottlenecks that hinder development of new antibacterial drugs
Jean de Gunzburg, Chief Scientific Officer, Da Volterra
17:50
Panel discussion: Tackling the major bottlenecks that hinder development of new antibacterial drugs
Conrad Lichenstein, Chief Scientific Officer, Nemesis Bioscience
17:50
Panel discussion: Tackling the major bottlenecks that hinder development of new antibacterial drugs
Jean-Pierre Paccaud, Director of Business Development and Legal , Drugs for Neglected Diseases initiative (DNDi)
18:30
Chairman’s Closing Remarks and Close of Day One
Richard Bax, Senior Partner, TranScrip Partners
Day 2
8:30
Registration & Coffee
9:00
Chairman's Opening Remarks
Lloyd Czaplewski, Director, Chemical Biology Ventures
9:10
OPENING ADDRESS: What if there are no new antibiotics?
Lloyd Czaplewski, Director, Chemical Biology Ventures
9:50
Fighting multi-drug resistant gram-negative infections
Ankit Mahadevia, President and CEO, Spero Therapeutics
10:30
Morning Coffee
11:00
Antibiotic Resurrection: Taking the Path of Least Resistance
Conrad Lichenstein, Chief Scientific Officer, Nemesis Bioscience
11:40
Building a pipeline and framework for anti-microbial drugs
David Cook, Chief Scientific Officer , Blueberry Therapeutics Ltd.
12:20
Networking Lunch
13:20
Clinical development of broad- spectrum anti-infective treatment drugs
Jean de Gunzburg, Chief Scientific Officer, Da Volterra
14:00
Determining preclinical PK/PD relationships for faster and accurate drug development
William Hope , Professor of Therapeutics and Infectious Diseases, University Of Liverpool
14:40
Antimicrobial peptides as viable alternatives
Steve Boakes, Head of Microbiology, Cantab Anti-infectives
15:20
Afternoon Tea
15:50
The use of combination antibiotic therapy
William J. Weiss, Director of Pre-Clinical Services, University of North Texas Health Science Center
16:30
Hyperbaric Oxygen Treatment as an adjunctive treatment to infectious diseases and its synergistic effects
Ole Hyldegaard, Medical Director, Associate Professor , University Hospital of Copenhagen
17:10
Microbiota host interactions as a starting point for antimicrobial strategies
Frank Schuren, Senior Scientist , TNO Pharma
17:50
Chairman’s Closing Remarks and Close of Day Two
Lloyd Czaplewski, Director, Chemical Biology Ventures

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report